These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 33206587)

  • 21. Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer.
    Powles T; Park SH; Voog E; Caserta C; Valderrama BP; Gurney H; Kalofonos H; Radulovic S; Demey W; Ullén A; Loriot Y; Sridhar SS; Tsuchiya N; Kopyltsov E; Sternberg CN; Bellmunt J; Aragon-Ching JB; Petrylak DP; Laliberte RJ; Huang B; Costa N; Blake-Haskins JA; Grivas P
    Future Oncol; 2022 Jun; 18(19):2361-2371. PubMed ID: 35416053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How Assessment-Schedule Matching Limits Bias When Comparing Progression-Free Survival in Single-Arm Studies: An Application in Second-Line Urothelial Carcinoma Treatments.
    Kapetanakis V; Prawitz T; Schlichting M; Ishak KJ; Phatak H; Yu T; Bharmal M
    Value Health; 2021 Aug; 24(8):1137-1144. PubMed ID: 34372979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced Urothelial Carcinoma.
    Lapuente M; Conway D; Wood LS; Kehoe K; Carroll Bullock A; Devgan G; Burns KD
    Clin J Oncol Nurs; 2023 Jan; 27(1):71-80. PubMed ID: 37677821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma.
    Coquan E; Clarisse B; Lequesne J; Brachet PE; Nevière Z; Meriaux E; Bonnet I; Castera M; Goardon N; Boutrois J; Travers R; Joly F; Grellard JM; Thiery-Vuillemin A
    BMC Cancer; 2022 Nov; 22(1):1213. PubMed ID: 36434554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
    Zacharis A; Grüllich C
    Urologe A; 2020 Jul; 59(7):797-803. PubMed ID: 32500171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Re: Srikala S. Sridhar, Thomas Powles, Miguel. Á. Climent Durán, et al. Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance. Eur Urol 2024:85:154-63.
    Zhou W; Zu X; Hu J
    Eur Urol; 2024 Oct; 86(4):e96. PubMed ID: 38811315
    [No Abstract]   [Full Text] [Related]  

  • 27. Pembrolizumab for the treatment of bladder cancer.
    Sundahl N; Rottey S; De Maeseneer D; Ost P
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic role of circulating cytokines and inflammation indexes for avelumab maintenance in metastatic urothelial carcinoma.
    Maiorano BA; Schinzari G; Carbone C; Piro G; Rossi E; Di Maio M; Di Giacomo A; Maiello E
    Front Immunol; 2024; 15():1401214. PubMed ID: 38799450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland.
    Critchlow S; Bullement A; Crabb S; Jones R; Christoforou K; Amin A; Xiao Y; Kapetanakis V; Benedict Á; Chang J; Kearney M; Eccleston A
    Future Oncol; 2024 Mar; 20(8):459-470. PubMed ID: 37529943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis.
    Tomita Y; Yamamoto Y; Tsuchiya N; Kanayama H; Eto M; Miyake H; Powles T; Yoshida M; Koide Y; Umeyama Y; di Pietro A; Uemura H
    Int J Clin Oncol; 2022 Feb; 27(2):383-395. PubMed ID: 34973108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.
    Sridhar SS; Powles T; Climent Durán MÁ; Park SH; Massari F; Thiery-Vuillemin A; Valderrama BP; Ullén A; Tsuchiya N; Aragon-Ching JB; Gupta S; Petrylak DP; Bellmunt J; Wang J; Laliberte RJ; di Pietro A; Costa N; Grivas P; Sternberg CN; Loriot Y
    Eur Urol; 2024 Feb; 85(2):154-163. PubMed ID: 37714742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study.
    Verschraegen CF; Jerusalem G; McClay EF; Iannotti N; Redfern CH; Bennouna J; Chen FL; Kelly K; Mehnert J; Morris JC; Taylor M; Spigel D; Wang D; Grote HJ; Zhou D; Munshi N; Bajars M; Gulley JL
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32907924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Re: Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
    Gakis G
    Eur Urol; 2021 May; 79(5):702. PubMed ID: 33390284
    [No Abstract]   [Full Text] [Related]  

  • 34. Re: Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
    Grimm MO; Leucht K
    Eur Urol; 2021 Mar; 79(3):429-430. PubMed ID: 33148473
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States.
    Criss SD; Weaver DT; Sheehan DF; Lee RJ; Pandharipande PV; Kong CY
    Urol Oncol; 2019 Mar; 37(3):180.e11-180.e18. PubMed ID: 30528699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial.
    Vaishampayan U; Schöffski P; Ravaud A; Borel C; Peguero J; Chaves J; Morris JC; Kotecki N; Smakal M; Zhou D; Guenther S; Bajars M; Gulley JL
    J Immunother Cancer; 2019 Oct; 7(1):275. PubMed ID: 31651359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How I Do It: Maintenance avelumab for advanced urothelial carcinoma.
    Lalani AA
    Can J Urol; 2023 Aug; 30(4):11633-11638. PubMed ID: 37633293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program.
    Walker JW; Lebbé C; Grignani G; Nathan P; Dirix L; Fenig E; Ascierto PA; Sandhu S; Munhoz R; Benincasa E; Flaskett S; Reed J; Engelsberg A; Hariharan S; Kasturi V
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32269140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer: Practical Implementation Steps for Infusion Nurses.
    Wood LS; Conway D; Lapuente M; Salvador G; Fernandez Gomez S; Carroll Bullock A; Devgan G; Burns KD
    J Infus Nurs; 2022 May-Jun 01; 45(3):142-153. PubMed ID: 35537002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-World Treatment Patterns, Sequencing, and Outcomes in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Receiving Avelumab First-Line Maintenance in the United States.
    Moon HH; Kearney M; Mahmoudpour SH; Ike C; Morris V; Rava A; Kim S; Sun H; Boyd M; Gomez Rey G
    Curr Oncol; 2024 Sep; 31(9):5662-5676. PubMed ID: 39330048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.